parallel randomized trial

S002938

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Type 2 diabetes (adults)Chronic kidney disease with diabetesS002938

Design

Randomized: 84
Start year: 2017
Treatment: 12 weeks, follow-up 12 weeks
Countries: China (1 sites)
Sponsor: (non industry)
Eligibility: age 18 to 65; GLP-1RA naive; diabetic nephropathy

Conduct and analysis

Blinding: not reported
Sequence generation: other adequate
Allocation concealment: not reported
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population
Missing data

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Standard care or no added treatment Conventional treatment	diet, exercise education, oral drugs or insulin, blood pressure and lipid treatment; lifestyle: standard	42	42
A2	Liraglutide subcutaneous once daily, flexible dose: 1.2 or 1.8 mg by tolerability Liraglutide plus conventional treatment	diet, exercise education, oral drugs or insulin, blood pressure and lipid treatment; lifestyle: standard	42	42

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Standard care or no added treatment A1	Liraglutide subcutaneous once daily, flexible dose: 1.2 or 1.8 mg by tolerability A2
age	max (years)	63	65
age	mean (years)	45.38	46.89
age	min (years)	36	38
age	sd (years)	10.34	11.26
bmi	mean (kg/m2)	27.42	27.83
bmi	sd (kg/m2)	2.21	2.71
diabetes duration	mean (years)	9.37	10.04
diabetes duration	sd (years)	5.81	6.12
female	n	20	21
hba1c	mean (percent)	9.81	9.98
hba1c	sd (percent)	0.96	0.87
other uaer	mean (μg/min)	288.62	282.47
other uaer	sd (μg/min)	32.24	31.86

Results

2 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

HbA1c change (2 lines; O01)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
12	A1	final	7.16 percent	0.62		42	not stated; other; R0005474:Table I
12	A2	final	6.45 percent	0.51		42	not stated; other; R0005474:Table I